Pfizer asks FDA to clear Covid pill for high-risk patients

Paxlovid is second oral antiviral to undergo FDA review as drugmaker moves to widen access to oral treatment

17 November 2021 - 20:38 By Riley Griffin

Pfizer has asked US regulators for emergency-use authorisation of its Covid-19 pill that could play a critical role in further protecting high-risk patients from the disease’s worst effects. 

The drug, Paxlovid, blocks a crucial enzyme that’s key to the growth of the coronavirus and would be the first of its sort if cleared, Pfizer said in a statement. Unlike most other Covid treatments, it could be prescribed for home use...

This article is reserved for Sunday Times subscribers.

A subscription gives you full digital access to all Sunday Times content.

Already subscribed? Simply sign in below.

Registered on the BusinessLIVE, Business Day or Financial Mail websites? Sign in with the same details.

Questions or problems? Email or call 0860 52 52 00.